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ABSTRACT
Solid tumors are much more common than
hematologic malignancies. Although severe and
prolonged neutropenia is uncommon, several
factors increase the risk of infection in patients
with solid tumors, and the presence of multiple
risk factors in the same patient is not uncom-
mon. These include obstruction (most often
caused by progression of the tumor), disruption
of natural anatomic barriers such as the skin
and mucosal surfaces, and treatment-related
factors such as chemotherapy, radiation, diag-
nostic and/or therapeutic surgical procedures,
and the increasing use of medical devices such
as various catheters, stents, and prostheses.
Common sites of infection include the skin and
skin structures (including surgical site infec-
tions), the bloodstream (including infections
associated with central venous catheters), the
lungs, the hepato-biliary and intestinal tracts,
and the urinary tract, and include distinct
clinical syndromes such as post-obstructive
pneumonia, obstructive uropathy, and neu-
tropenic enterocolitis. The epidemiology of
most of these infections is changing with resis-
tant organisms [MRSA, Pseudomonas aeruginosa,
extended spectrum beta-lactamase (ESBL)-pro-
ducing organisms] being isolated more often
than in the past. Polymicrobial infections now
predominate when deep tissue sites are
involved. Conservative management of most of
these infections (antibiotics, fluid and elec-
trolyte replacement, bowel rest when needed) is
generally effective, with surgical intervention
being reserved for the drainage of deep absces-
ses, or to deal with complications such as
intestinal obstruction or hemorrhage. Infected
prostheses often need to be removed. Reactiva-
tion of certain viral infections (HBV, HCV, and
occasionally CMV) has become an important
issue, and screening, prevention and treatment
strategies are being developed. Infection pre-
vention, infection control, and antimicrobial
stewardship are important strategies in the
overall management of infections in patients
with solid tumors. Occasionally, infections
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INTRODUCTION
The National Cancer Institute has defined solid
tumors as non-cystic masses (either benign or
malignant) including carcinomas, lymphomas,
and sarcomas. It has been estimated that
1,685,210 new cases of cancer will be diagnosed
in the United States in 2016, with an estimate of
more than 14 million new cases worldwide [1].
The vast majority will be solid tumors with
cancers of the breast, lungs and bronchus,
prostate, colon and rectum, and urinary bladder
being the most common, whereas leukemias
will account for approximately 4% of new cases.
Infections are the most common complications
seen in cancer patients, and occur as a result of
the underlying malignancy and of the various
modalities used for treatment. Despite the fact
that solid tumors are far more common, infec-
tions in patients with solid tumors have not
been studied as well as in patients with hema-
tologic malignancies [2, 3]. Unlike the latter,
most patients with solid tumors are not signifi-
cantly immunosuppressed and do not experi-
ence prolonged periods of neutropenia. Instead,
factors that increase the risk of infection in
these patients include damage to normal ana-
tomic barriers, such as the skin and mucosal
surfaces, obstructive phenomena (common in
patients with lung, hepato-biliary, pancreatic,
intestinal, prostatic and gynecologic tumors),
surgical procedures, chemotherapy, radiation,
central nervous system dysfunction, nutritional
factors, and the increasing use of medical devi-
ces (catheters, stents, shunts, and prostheses)
[4]. Common sites of infection include the res-
piratory tract, the bloodstream (including cen-
tral line-associated bloodstream infections), the
urinary tract, and skin and skin structures (in-
cluding surgical site infections). In recent years,
the epidemiology of most of these infections
has changed with the emergence of resistant
organisms. Consequently, newer therapeutic
approaches need to be developed based on local
epidemiologic and susceptibility/resistance
data. Additionally, infection prevention, infec-
tion control, and antimicrobial stewardship are
important and often underrated and neglected
strategies in this setting [5].
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RISK FACTORS FOR INFECTION
As indicated above, several factors increase the
risk of infection in solid tumor patients
(Table 1). The presence of multiple risk factors
in the same patient is not uncommon, further
increasing risk. These factors are discussed in
detail below.
Neutropenia
Neutropenia is defined as an absolute neu-
trophil count (ANC) of \500 cells/mm3. The
most frequent cause of neutropenia is antineo-
plastic chemotherapy. Varying degrees of neu-
tropenia also occur after radiation therapy or
the administration of other myelosuppressive
agents (e.g., ganciclovir), and occasionally after
extensive infiltration of the bone marrow by
spreading tumor. Unlike patients with hema-
tologic malignancies, most patients with solid
tumors have normally functioning neutrophils.
Additionally, conventional chemotherapy
rarely produces severe neutropenia lasting
longer than 7 days. Consequently, the ‘‘at risk’’
period is generally short and many solid tumor
patients who develop neutropenic fever are
considered low risk [6, 7]. Newer treatment
strategies for low-risk neutropenic patients have
been developed and include early discharge
after a short period of hospitalization, or man-
agement of the entire episode of neutropenic
fever without hospitalization [8–10]. Specific
guidelines for the management of febrile neu-
tropenic patients with underlying solid tumors
have recently been published [11]. These
guidelines stress the importance of performing
risk assessment in order to identify low-risk
patients who can be treated in an ambulatory
setting, since hospitalization is associated with
several drawbacks including iatrogenic errors
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and exposure to healthcare associated, mul-
tidrug-resistant microflora. Safety, however, is
paramount, and ambulatory/outpatient man-
agement should only be implemented if the
appropriate infrastructure to support this activ-
ity around the clock exists [9, 10].
Disruption of Anatomic Barriers
Normal anatomic barriers such as the skin and
various mucosal surfaces (oro-pharyngeal, gas-
tro-intestinal, respiratory, and genito-urinary)
provide an important natural defense mecha-
nism against invading pathogens. Cancer
chemotherapy often damages mucosal surfaces,
thereby increasing the risk of infections caused
by organisms that colonize these surfaces [e.g.,
viridans group streptococci (VGS), Streptococcus
pneumoniae, Stomatococcus mucilaginosus, enteric
Gram-negative bacilli, and anaerobes]. Agents
that frequently cause mucositis include
5-fluorouracil (5-FC), capecitabine (a pro-drug
of 5-FU), cyclophosphamide, ifosfamide, cis-
platin and carboplatin. The taxanes (docetaxel
and paclitaxel) and vinorelbine have also been
associated with significant mucositis. Damage
to mucosal barriers is also caused by radiation
therapy, surgical procedures, and the use of
medical devices. Tumors may cause local ero-
sion and fistula formation (e.g., broncho-pleu-
ral, trachea-esophageal, vesico-vaginal or
recto-vaginal). Protection provided by the skin
is also breached by surgical procedures and
radiation, and by medical devices such as
catheters and percutaneous endoscopic gas-
trostomy (PEG)-tubes [12].
Obstruction of Normal Passages
Obstruction caused by expanding tumors is
relatively common in solid tumor patients.
Bronchogenic carcinomas (or metastatic
Table 1 Factors that increase the risk of infection in patients with solid tumors
Risk factor(s)a Additional explanatory comments
Neutropenia Chemotherapy, radiation therapy, bone marrow inﬁltration with tumor, drugs
(e.g., ganciclovir)
Disruption of anatomic barriers (e.g.,
skin, mucosal surfaces)
Chemotherapy (mucositis), radiation therapy, vascular access catheters, urinary
catheters, percutaneous endoscopic gastrostomy tubes and other medical
devices, surgical/diagnostic procedures
Obstruction due to primary or
metastatic tumor
Airways: post-obstructive pneumonia, lung abscess, empyema, ﬁstula formation
(e.g., broncho-pleural or trachea-esophogeal)
Biliary tract: ascending cholangitis, hepatic and pancreatic abscess
Bowel: bowel obstruction, necrosis, perforation, peritonitis, hemorrhage
Urinary tract: urinary tract infection, renal abscess, prostatitis or prostatic abscess
Procedure and devices Diagnostic/therapeutic surgery: surgical site infections, wound dehiscence, abscess
formation
Shunts: disseminated infection (bacteremia) shunt-related infections such as
meningitis/ventriculitis, hepato-biliary infections, complicated urinary tract
infections
Prosthetic devices: infected prosthesis, osteomyelitis and/or septic arthritis, local
abscess formation, disseminated infection
Miscellaneous factors Age, nutritional status, prior antibiotic exposure, loss of gag reﬂex
a Multiple risk factors frequently occur in the same patient
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pulmonary lesions) often cause airways
obstruction leading to the development of
post-obstructive pneumonia, which may occa-
sionally be the initial manifestation of these
tumors [13]. As obstruction increases, lung
abscess, fistula formation, or empyema may
occur [14]. Biliary tract obstruction in patients
with hepato-biliary and pancreatic tumors
results in ascending cholangitis and hepatic
abscess formation. Ureteral obstruction result-
ing in hydronephrosis and complicated urinary
tract infection is commonplace in patients with
carcinoma of the cervix and other gynecologic
tumors. Patients with prostatic carcinoma also
develop prostatitis, complicated urinary tract
infections, and occasionally prostatic abscesses.
Intestinal tumors can lead to partial or complete
bowel obstruction, ileus, perforation, peritoni-
tis, hemorrhage, and/or abdominal/pelvic
abscess formation. In these situations, mixed or
polymicrobial infections are the norm, and the
etiologic agents are generally those that colo-
nize the site of obstruction.
Procedures and Devices
Surgery, medical procedures, radiation therapy,
and the widespread and increasing use of cathe-
ters and other devices is often associatedwith the
development of infection [15]. The use of mul-
tiple-lumenvascular access catheters has become
commonplace and greatly facilitates the drawing
of blood and the administration of various enti-
ties such as chemotherapy, antimicrobial agents,
blood and blood products, and fluids. The major
complication associated with these catheters is
infection. The organisms causing catheter-re-
lated infections are predominantly those that
colonize human skin. Approximately 70–80%
are Gram-positive, with Staphylococcus species
being isolated most often. Gram-negative
organisms and fungi (mostly Candida spp.) are
much less common, and 5–10% of these infec-
tions are polymicrobial. Urinary catheters are
used when obstruction or urinary incontinence
is present.Occasionally, local involvementof the
ureters or urinary bladder may require the cre-
ation of surgical diversions into ileal or colonic
segments. Acute or chronic pyelonephritis,
sometimes progressing to bacteremia (urosepsis),
may occur. Theuse of nephrostomy tubesmaybe
associatedwith similar complications [16].Many
patients with central nervous system (CNS)
tumors require the placement of shunts in order
to relieve intracranial pressure. When infected,
the CNS end of these shunts produce symptoms
such as headache, mental status changes, and
meningismus, whereas the distal ends of these
shunts (which are generally located in thepleural
or peritoneal cavities) give rise to symptoms of
pleuritis or peritonitis. Surgically implanted
prosthetic devices are used often in patients with
osteosarcoma or other bone/cartilage tumors.
Infection is the most common complication
associated with these devices, and may require
removal of the device for resolution of the
infection. Patients with head and neck and eso-
phageal cancers often require the placement of
PEG-tubes in order to ensure adequate nutrition.
Insertion site infections, abdominal wall infec-
tions/abscesses, perforationwith peritonitis, and
occasionally bacteremic infections may occur,
but are uncommon [12].
Miscellaneous Factors
Patients with CNS tumors often develop partial
loss of the gag reflex which predisposes them to
aspirate oro-pharyngeal secretions. Neurologic
abnormalities resulting in impaired micturition
can also occur. Radiation can damage ciliary
function resulting in aspiration and pneumo-
nia. In elderly patients, immunologic deficits
caused by ageing, malnutrition, and cancer
cachexia may also have an impact on the fre-
quency and severity of infection and the overall
response to therapy. Prior or concurrent
antimicrobial usage can result in the selection
of resistant organisms. Antimicrobial steward-
ship and strict adherence to infection control
recommendations and policies are important
tools in limiting the emergence and spread of
such infections.
COMMON SITES OF INFECTION
Common sites of infection largely depend on
the location and size of the tumor and/or the
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site and nature of the medical device in use, the
surgical procedure performed, and the site and
intensity of radiation (Table 2). Surgical site
infections are among the most common. Recent
data indicate that the epidemiology of these
infections has changed significantly. Whilst
Gram-positive organisms still predominate, the
proportion caused by methicillin-resistant S.
aureus (MRSA) has increased substantially com-
pared to 10–15 years ago. Additionally,
Gram-negative and polymicrobial surgical site
infections appear to be increasing [17]. These
changes require modifications to current rec-
ommendations for infection prevention and
treatment.
Bloodstream infections, including those
associated with central venous catheters and
other vascular access devices, are among the
most common infections seen in solid tumor
patients [18]. The spectrum of these infections
is changing with an increased frequency of
Gram-negative bacilli, many of which are mul-
tidrug-resistant, being reported [18]. The lungs
represent one of the most common sites of
infection in patients with solid tumors [19]. As
previously mentioned, aspiration pneumonia is
common in patients with impaired gag reflex
and/or ciliary function, whereas post-obstruc-
tive pneumonia is common in patients with
primary or metastatic lung cancers. Infections
involving the hepato-biliary and gastro-intesti-
nal tracts also occur frequently and are associ-
ated with a common set of manifestations
which may give rise to diagnostic and thera-
peutic challenges [20]. Obstructive uropathy
and complicated urinary tract infections go
hand in hand and are often recurrent and dif-
ficult to eradicate. Specific infections/syn-
dromes at these sites will be discussed in greater
detail below.
Table 2 Common sites of infection in patients with solid tumors
Infection site Comments
Bloodstream Often associated with vascular access catheters and neutropenia. Changing epidemiology, with
resistant Gram-negative organisms emerging
Breast Generally related to breast cancer surgery, including reconstruction and implants. Changing
epidemiology with MRSA and Gram-negative organisms common
Bone, cartilage, joints Often surgery- or prosthetic device-related. May require device removal and/or long-term
suppressive therapy
Central nervous system Including ventriculitis, meningitis, shunt-related infections, and post-surgical infections
Skin and skin structure Most often related to surgery, including invasive diagnostic procedures. May be chronic or
persistent in irradiated areas. Poly-microbial infections are common
Respiratory tract Aspiration pneumonia in patients with loss of gag reﬂex or ciliary function. Post-obstructive
pneumonia (with empyema or ﬁstula formation with progressive disease)
Hepato-biliary pancreatic Ascending cholangitis (±bacteremia); local abscess formation, reactivation of viral infections
(HBV, HCV, CMV)
Upper gastro-intestinal Tracheo-esophageal ﬁstula; percutaneous endoscopic gastrostomy (PEG)-tube-related infection,
gastric perforation with abscess formation or peritonitis
Lower gastro-intestinal,
pelvic
Bowel perforation with peritonitis or abscess formation, neutropenic enterocolitis, Clostridium
difﬁcile- or CMV-associated colitis; perirectal/peri-anal infection
Genitourinary tract and
prostate
Complicated urinary tract infections; obstructive uropathy; prostatitis; abdominal and/or pelvic
abscesses
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CURRENT MICROBIOLOGY
OF INFECTION
Most infections in patients with solid tumors
are caused by the individual patients’ resident
microflora. Consequently, the distribution of
causative organisms mirrors the normal micro-
flora at a particular site of infection [4, 21].
Acquisition of nosocomial or healthcare-asso-
ciated pathogens generally occurs several days
after hospitalization, although, in recent years,
the site of care has shifted to a great extent to
clinics and out-patient oncology centers,
wherein healthcare-associated infections are
also commonplace. Prolonged or multiple
antibiotic exposure, which often occurs in solid
tumor patients, leads to the selection of resis-
tant organisms. Geographic and local (institu-
tional) differences in microbiology and
susceptibility/resistance patterns are not infre-
quent and must always be taken into account




Bloodstream infections occur predominantly in
patients with indwelling central venous cathe-
ters and other vascular access devices as well as
in patients with significant oral or intestinal
mucositis. Bloodstream infections are more
common in such patients when they develop
episodes of neutropenia. Unlike patients with
hematologic malignancies, most patients with
solid tumors do not receive antimicrobial pro-
phylaxis following chemotherapy. Such pro-
phylaxis is directed primarily against
Gram-negative organisms. Consequently, in the
absence of prophylaxis, Gram-negative BSIs are
more common than Gram-positive BSIs in
patients with solid tumors. [18]. Escherichia coli,
Klebsiella species, and Pseudomonas aeruginosa
are the most common Gram-negative species
isolated [22]. Non-fermentative Gram-negative
bacilli are emerging as significant pathogens at
some institutions. These include Acinetobacter
species, Stenotrophomonas maltophilia, Achro-
mobacter species, and non-aeruginosa Pseu-
domonas species, many of which are
multidrug-resistant [23]. Staphylococci, strep-
tococci, and enterococci are the predominant
Gram-positive pathogens isolated. At many
institutions, more than 90% of coagulase-neg-
ative staphylococci (CoNS) and more than 50%
of S. aureus are methicillin-resistant, and
15–20% of Enterococcus species are van-
comycin-resistant. A minority of BSIs are fun-
gal, caused almost exclusively by Candida
species. Anaerobes are seldom isolated from
blood cultures.
Post-obstructive Pneumonia
Post-obstructive pneumonia is defined as infec-
tion of the lung parenchyma caused by bron-
chial obstruction [24]. In most cases, the
obstruction is caused by a neoplasm, and
post-obstructive pneumonia may be the initial
manifestation of malignancy in 40–50% of
patients with this diagnosis [13]. Fever, cough,
sputum production, and weight loss are com-
mon. Leucocytosis is also common unless
chemotherapy-induced myelosuppression is
present. Other symptoms include dyspnea,
pleuritic chest pain, and hemoptysis. Symptoms
persist and worsen as the degree of obstruction
increases. Since the infection is located below
the level of obstruction, respiratory samples
from above this level are often negative. In
many cases, Invasive diagnostic procedures
such as percutaneous lung aspiration/biopsy
may be the most accurate way of determining
the etiology. Microbiologic data are often diffi-
cult to interpret, and generally reveal polymi-
crobial flora [25, 26]. These include Streptococcus
species such as S. pneumoniae, beta-haemolytic
streptococci, and viridans group streptococci;
Staphylococcus species including methicillin-re-
sistant isolates, Gram-negative bacilli such as
the Enterobacteriaceae and Pseudomonas aerugi-
nosa, and some anaerobes. Candida species are
also frequently isolated, but their role in this
infection is unclear. Most patients are treated
with broad spectrum antimicrobial regimens
directed against the pathogens outlined above.
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Despite such therapy, responses are often slow,
and complete defervescence generally does not
occur, with persistent or recurrent infections
being common. Approximately 10–15% of
patients with chronic or progressive post-ob-
structive pneumonia develop serious complica-
tions such as lung abscess, hemorrhage,
empyema, and fistula formation (bron-
cho-pleural or trachea-esophageal). A vicious
cycle often ensues, as these complications fre-
quently cause delays in the administration of
antineoplastic therapy, which can lead to
worsening of the obstruction. Consequently,
full attention should be focused on treating the
lesion(s) causing obstruction. Several options to
accomplish this are available including low- or
high-dose-rate brachytherapy, cryotherapy,
laser therapy, electro-cautery, and the place-
ment of airways stents [27, 28]. Unfortunately,
despite these measures, progressive, ultimately
fatal, disease is the norm [14].
Infections Associated with Breast Cancer
Surgery
Breast cancer is the most common cancer in
women worldwide and its frequency has been
increasing in recent years [1, 29–31]. Most of
these patients undergo some surgical procedure
of the involved breast along with ipsilateral
lymph node dissection. Several forms of breast
reconstruction are also frequently performed.
These include autologous reconstruction using
a transverse rectus abdominis musculo-cuta-
neous flap, or a deep inferior epigastric artery
perforator flap [31]. Prosthetic reconstruction
using silicone or saline implants is also widely
used. Although a detailed discussion of the
various surgical/reconstruction procedures is
beyond the scope of this review, all these pro-
cedures are associated with an infection rate
that ranges between 2.5% and 24% [32, 33].
Infection is a leading cause of hospital admis-
sion in such patients, and can result in devas-
tating medical/surgical, psycho-social, and
financial consequences. Factors that increase
the risk of infection include increased body
mass index, radiation therapy (which also
retards healing), axillary lymph node
dissection, the use of surgical drains, adjuvant
chemotherapy, and possibly tobacco use
[34–37]. Staphylococci (CoNS and S. aureus) are
involved in almost all such infections, with the
majority of isolates being methicillin-resistant.
However, several recent studies indicate that a
small but significant proportion of these infec-
tions are caused by Gram-negative bacilli such
as E. coli, P. aeruginosa, and Klebsiella species
[38–40]. Non-tuberculous mycobacterial and
polymicrobial infections are less common but
are difficult to manage [41]. With a significant
rate of, and changing epidemiology of, infec-
tion in this setting, infection prevention has
become extremely important. Antimicrobial
prophylaxis is an important infection preven-
tion strategy. Breast surgery is considered clean
surgery by the Center for Disease Control and
Prevention (CDC) and the Surgical Care
Improvement Project, and current guidelines
suggest a maximum of 24 h of peri-operative
antibiotics [42]. Agents commonly used for
antimicrobial prophylaxis (predominantly first-
and second-generation cephalosporin) were
chosen several decades ago and do not provide
adequate coverage against organisms (MRSA, P.
aeruginosa) mentioned above [39, 43]. Several
investigators have recommended alternative
regimens based on local epidemiology and sus-
ceptibility/resistance patterns [44–46]. Since
most of the procedures are elective, some rec-
ommend screening patients for MRSA and P.
aeruginosa and providing targeted prophylaxis
when these organisms are detected, or using
agents with activity against these organisms in
empiric regimens [47–49].
Hepato-biliary Infection
Obstruction of the biliary tract as a result of
hepato-biliary or pancreatic tumors results in
the development of ascending cholangitis [50].
Less frequently, single or multiple liver absces-
ses develop, especially in patients with persis-
tent obstruction [51]. These are being
documented with increasing frequency due to
improved imaging techniques. As with lung
neoplasms and post-obstructive pneumonia,
ascending cholangitis may be the initial
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manifestation of local neoplastic disease, and
may lead to its discovery during evaluation.
Hepatic abscesses have also been reported after
invasive procedures for hepatocellular carci-
noma, such as the administration of intra-arte-
rial chemotherapy [52, 53]. Most of these
infections are polymicrobial, with enteric
Gram-negative bacilli, Enterococcus species (in-
cluding VRE), and anaerobes being predomi-
nant [54]. Broad spectrum antimicrobial
therapy and percutaneous drainage are often
necessary in order to achieve adequate respon-
ses. Patients with hepatocellular carcinoma and
pancreatic head tumors often develop obstruc-
tive jaundice, which can progress to hepatic
failure. In this setting, percutaneous transhep-
atic biliary drainage (PTBD) has been used to
treat obstructive jaundice [55]. More recently,
endoscopic biliary stenting (EBS) is replacing
PTBD as the treatment of choice in this setting
[56]. Several studies have shown that internal
biliary drainage increases microbial coloniza-
tion of stents and the formation of sludge
which also contains intestinal microorganisms
[57]. The frequency of cholangitis appears to be
increased in such circumstances [57, 58].
Infections Involving the Intestinal Tract
The intestinal tract is a common site of infec-
tion in patients with solid tumors. Several
well-recognized syndromes have been described
in such patients, including appendicitis,
intestinal perforation with peritonitis and/or
local abscess formation, Clostridium difficile-as-
sociated colitis, cytomegalovirus (CMV) colitis,
and typhlitis or neutropenic enterocolitis [20].
The clinical manifestations associated with
most of these syndromes are similar, and
include abdominal symptoms (cramping, pain,
tenderness, distension), fever, diarrhea, and
intestinal hemorrhage. These manifestations
are not typical nor pathognomonic of any sin-
gle entity. Therefore, clinical features, radio-
graphic imaging findings, microbiologic,
serologic, and histopathologic data need to be
considered in order to make a specific diagnosis.
Conservative medical management (fluid and
electrolyte support, bowel rest, broad-spectrum
parenteral antibiotic therapy) is generally
effective. Surgical intervention is usually nee-
ded when complications such as intestinal per-
foration or bleeding develop.
In years gone by, neutropenic enterocolitis
(NEC) was seen primarily in patients with acute
leukemia receiving intensive cytotoxic
chemotherapy with agents such as cytosine
arabinoside or idarubicin [59–61]. NEC was
documented much less often in patients with
solid tumors. Recent reports have highlighted
an association between NEC and therapy with
taxanes (docetaxel, paclitaxel) and vinorelbine
[62–64]. These agents are often used to treat
solid tumors such as breast, lung, and ovarian
cancers. Pre-existing bowel abnormalities such
as diverticulosis/diverticulitis, bowel infiltration
with the underlying tumor, and prior surgery or
radiation may also increase the risk of devel-
opment of NEC following cytotoxic
chemotherapy. The onset of NEC usually occurs
in the third week of neutropenia (median
17 days) and coincides with maximal mucosal
damage. However, there are reports suggesting
earlier or later onset, sometimes even after res-
olution of neutropenia. In patients with the
abdominal symptoms outlined above, imaging
studies are the most reliable and accurate tools
for making a diagnosis of NEC. Computerized
tomography (CT) is the imaging option of
choice [65]. The most characteristic CT finding
is bowel wall thickening, usually around 7 mm
(range 4–15 mm). An important prognostic
finding is the presence of bowel wall thickening
of[10 mm which is associated with severe dis-
ease and poorer outcomes [66]. As mentioned
previously, general supportive measures such as
bowel rest with nasogastric suction and par-
enteral nutrition if necessary, along with fluid
and electrolyte replenishment, are generally
effective, with surgical intervention being
reserved for more serious complications.
Risk factors associated with C. difficile colo-
nization and disease include antibiotic usage,
proton-pump inhibitors or H2 blockers, previ-
ous hospitalization, and antineoplastic
chemotherapy [67]. Up to 6% of patients
receiving cisplatin therapy for ovarian carci-
noma develop C. difficile-associated colitis [68].
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Such therapy should subsequently be avoided
since relapse or recurrent infection can occur
[69]. Recent data suggest that vancomycin is
superior to metronidazole therapy for moderate
to severe infection. Fidaxomicin, a new macro-
cyclic agent, is similar to vancomycin with
regards to clinical response, but produces more
sustained responses and fewer relapses [70–72].
Fecal microbiota transplantation has been
shown to be efficacious in patients with multi-
ple recurrences [73].
CMV disease has not been well studied in
solid tumor patients. Although infrequently
reported, CMV testing is not routinely per-
formed in such patients, consequently reacti-
vation of CMV or active disease is probably
often unrecognized and underreported. One
retrospective analysis reported that at least 50%
of patients with solid tumors with a positive
CMV polymerase chain reaction also had clini-
cally relevant CMV disease requiring antiviral
therapy [74]. Although gastrointestinal CMV
disease is uncommon in patients with solid
tumors, it is associated with high morbidity and
mortality [75].
Hepatitis
Hepatitis virus infections (both hepatitis B
virus, HBV, and hepatitis C virus, HCV) are
relatively common worldwide. Recent estimates
suggest that more than 350 million individuals
globally have HBV infection and 130–170 mil-
lion are infected with HCV [76–78]. In oncology
settings, HBV reactivation rates vary between
30% and 80% depending on the HBV serologic
status and the specific chemotherapy regimen
[79]. Whilst reactivation can be asymptomatic,
it can lead to severe hepatitis, liver failure and
death [80]. It often leads to delays in antineo-
plastic chemotherapy which can result in
increased tumor-related mortality. Patients with
solid tumors who are hepatitis B surface antigen
(HBsAg)- or hepatitis B core antibody
(HBcAb)-positive are at risk for HBV reactivation
after the administration of cytotoxic
chemotherapy. The CDC recommends univer-
sal screening of individuals prior to the
administration of cytotoxic chemotherapy or
immunosuppressive therapy [81]. A recent sys-
tematic review and meta-analysis of HBV reac-
tivation and prophylaxis during chemotherapy
for solid tumors concluded that, in patients
with chronic HBV receiving such chemother-
apy, the risk of reactivation was similar to other
types of immunosuppressive therapy, and that
there was strong support for HBV screening and
antiviral prophylaxis prior to initiating such
therapy [82]. Other studies/groups have con-
firmed these findings [83, 84]. Preferred agents
for HBV prophylaxis include lamivudine, ente-
cavir, and tenofovir. Additionally, monitoring
of viral load and hepatic transaminases is rec-
ommended for patients who do not have active
HBV infection and are not receiving prophy-
laxis [85].
HCV reactivation in cancer patients has not
been as well studied as HBV reactivation. The
overall prevalence of HCV infection in cancer
patients ranges from 1.5% to 32% [86, 87].
However, very little is known about its natural
history, prophylaxis, treatment, and outcomes
in this patient population. HCV-positive
patients with cancer have a higher risk of
developing cirrhosis, progress to fibrosis more
rapidly, and have poorer virologic responses
[88]. Increased mortality has been reported in
patients with cancer who have HCV infection
compared to those who do not [89]. Addition-
ally, increased risk of reactivation has also been
reported in patients receiving targeted therapies
[90]. Although treatment and outcomes data in
cancer patients are limited, in the general pop-
ulation HCV therapy can cure infection, pre-
vent reactivation, delay progression to cirrhosis,
and reduce overall mortality [91, 92]. Guideli-
nes recently issued by the National Compre-
hensive Cancer Network state that all patients
receiving chemotherapy or immunosuppressive
therapy should be screened for HCV [85].
Although no specific treatment guidelines for
cancer patients exist, HCV therapy in this set-
ting has been shown to be feasible and to pre-
vent or decrease progression of liver disease. An
algorithm for the management of patients with
cancer and HCV infection has recently been
published [86].
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Obstructive Uropathy/Complicated
Urinary Tract Infections
Obstructive uropathy is common in patients
with solid tumors [16]. The resultant urinary
stasis leads to bacterial colonization and can
progress to the development of complicated
urinary tract infection and urosepsis. Acute or
chronic ureteral obstruction (most often uni-
lateral but occasionally bilateral) is a complica-
tion of advancing retroperitoneal or pelvic
malignancy. Prompt decompression of the
obstruction is required. Ureteral stents have
been used for the management of ureteral
obstruction in this setting. Silicone or poly-
urethane stents are most often used but may be
associated with significant failure rates. Metallic
stents have also been evaluated and are con-
sidered to be effective [16, 93–95]. Alternatively,
obstructions can be dealt with the placement of
percutaneous nephrostomy tubes. The use of
stents and nephrostomy tubes is associated with
a significant rate of pyelonephritis [16]. Organ-
isms causing these infections include Staphylo-
coccus species, Enterococcus species, E. coli, P.
aeruginosa, S. maltophilia, Klebsiella species, and
Candida species [16]. Eradication of such infec-
tions is difficult to accomplish and recurrent
infections are the norm. Long-term suppressive
antibiotic therapy may be necessary in patients
who develop frequent bouts of urosepsis.
INFECTIONS MIMICKING CANCER
Occasionally, certain infections produce clinical
manifestations and/or radiographic images that
cannot be readily distinguished from those
produced by neoplasms. When such lesions are
detected, the most common suspicion is that of
metastatic or recurrent neoplasm, but, in a
small proportion of patients, are caused by an
infection. These lesions also need to be evalu-
ated promptly and a specific etiology estab-
lished, since the management of recurrent
neoplastic disease is totally different from that
of infection.
SUMMARY
Patients with hematologic malignancies often
develop infections, especially during episodes of
neutropenia. Since this is a relatively homoge-
nous group of patients compared to patients
with solid tumors, it has been well studied.
Several societies have developed and published
guidelines for the management of neutropenic
patients [8, 9, 85, 96]. Infections also represent a
Table 3 Infection-related clinical syndromes commonly seen in patients with solid tumors
Clinical syndrome Comments
Post-obstructive pneumonia Frequent in patients with primary or metastatic lung lesions. Sometimes the initial
manifestation of malignancy. Complications include lung abscess, ﬁstula formation, or
empyema. Treatment failures common
Obstructive uropathy Common in patients with genitourinary and prostatic tumors. Complicated urinary tract
infections and multidrug-resistant organisms are frequent
Reactivation of viral
infections
Hepatitis B virus and hepatitis C virus, usually following chemotherapy or
immunosuppressive therapy. Screening for all patients scheduled to receive chemotherapy is
recommended as is HBV prophylaxis for patients with HBV infection
Clostridium difﬁcile
associated disease
Multiple risk factors (antibiotics, chemotherapy, local anatomical factors). Recurrent
infections/relapses common. Newer therapies (ﬁdaxomicin, fecal microbiota
transplantation) have been developed
Neutropenic enterocolitis Associated with taxanes (docetaxel and paclitaxel), vinorelbine, and other agents producing
severe mucositis
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significant problem in patients with solid
tumors and this is a much more heterogenous
group. These infections are quite different from
the infections seen in patients with hemato-
logic malignancies, especially those with neu-
tropenia, and have generally been less well
studied. Many of these infections are related to
the tumor itself, due mostly to obstruction or
disruption of natural anatomic barriers. Others
are related to various treatment modalities
(chemotherapy, radiation, surgery, targeted
therapies). Recent data regarding many aspects
of such infections are scant. This review pro-
vides an update and discusses in detail syn-
dromes such as NEC, post-obstructive
pneumonia, breast cancer surgery-related
infections, and reactivation of hepatitis virus
infections, which have either become more
common or are being newly described/studied
in solid tumor patients (Table 3). The changing
epidemiology of infections, with the emergence
of resistant organisms has been highlighted,
and the role of infection control in preventing
the spread of such infections, as well as the role
of antimicrobial stewardship in preserving the
useful life of antimicrobial agents, has been
stressed. Very rarely, certain infections may
mimic cancer. These conditions need to be dif-
ferentiated promptly so that appropriate ther-
apy can be delivered.
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